Crow Point Partners’s AbbVie ABBV Stock Holding History

Crow Point Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-872	Closed	-$83K	–	122
2018 Q1	$83K	Buy	+872	New	+$95.8K	0.02%	149

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Crow Point Partners's ABBV Position: Q2 2018 in Review

Crow Point Partners sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 872 shares — an estimated $83K sold.

Crow Point Partners first reported a position in ABBV in Q1 2018 and held it in 1 quarter. The position peaked at $83K in Q1 2018. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Crow Point Partners reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Crow Point Partners sold 872 AbbVie shares in Q2 2018, an estimated $83K.
Crow Point Partners first reported a position in AbbVie in Q1 2018 and held it in 1 quarter.
Crow Point Partners's AbbVie position peaked at $83K in Q1 2018.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Crow Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.